Ditto, an Amsterdam-based health-tech building AI-generated summaries of medical appointments for patients, has raised €7.6m, the company said on Monday.
The round is led by Heal Capital with participation from Rubio Impact Ventures. Earlier backer Chris Oomen, chair of Optiverder, has also participated. The funding will support expansion into Germany, the UK, and Spain this year and continued development of the company’s consumer product.
Ditto was founded by CEO Tobias Lensing alongside co-founders Bart Voorn and Merlijn van Breugel after Lensing accompanied a friend with stage-4 bile-duct cancer to an oncology appointment and realised the two had walked away with materially different understandings of what the doctor said.
The company says patients typically remember 20% to 40% of what is communicated in a medical consultation.
The 💜 of EU tech
The latest rumblings from the EU tech scene, a story from our wise ol’ founder Boris, and some questionable AI art. It’s free, every week, in your inbox. Sign up now!
The product is a mobile app that records the consultation with the patient’s consent and generates a structured, plain-language summary that the patient can revisit, share with family, and use to prepare for follow-up appointments.
The position runs counter to the prevailing direction of AI in healthcare, which has focused on clinician-side tools for note-taking, triage, and chart-completion. Ditto argues that the lower-cost, higher-leverage opportunity is on the patient side.
The company launched in the Netherlands with the support of the national Patient Federation, targeting 10,000 downloads in six months.
Ditto says it hit that figure in under two weeks and is now approaching 100,000 users in the Netherlands, with 4.7-star ratings on both the App Store and Google Play. The company recently won the Dutch Healthcare Innovation Award.
Lensing said in the announcement that the company’s design choice is the strategic point. “Almost every AI company in healthcare today is building for doctors,” Lensing said.
“All useful. But nobody is building for the person on the other side of the desk: the one who actually has to live with the diagnosis, remember the instructions, and explain it to their family that evening.”
He framed the platform as a leverage point on patient outcomes: “The strongest medicine isn’t a drug. It’s a patient who knows what’s going on.”
Ditto is free for patients. The company is funded through partnerships with insurers, patient organisations and healthcare institutions, on the basis that the same summary that informs a patient also reduces follow-up calls, repeat explanations and missed appointments on the clinician side.
The company says it will go deeper into the patient journey, helping users prepare for upcoming appointments based on their consultation history rather than only summarising past ones.
Heal Capital is one of Europe’s most active health-tech investors; Rubio Impact Ventures brings an impact mandate aimed at populations the press release describes as those “the system already overlooks.”
The company did not disclose its post-money valuation or revenue. Ditto is governed under the EU AI Act and publishes its compliance posture on its website.
